Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis

Overview

Journal Adv Ther

Date 2022 Jul 17

PMID 35842897

Authors

Alexander Nedoshivin

Parvoleta T S Petrova

Yuri Karpov

Affiliations

Soon will be listed here.

Abstract

Introduction: Beta-blockers are recommended by the European Society of Cardiology as first-line antianginal therapy for reducing heart rate (HR) and symptoms in patients with chronic coronary syndrome, despite a lack of data showing superiority to other antianginal agents. Most patients with angina pectoris require combination therapy to manage symptoms, with a second-line agent chosen to manage the predominant cardiovascular problem. Ivabradine, a selective sinus node I channel inhibitor shown to reduce HR and protect against anginal symptoms, has previously demonstrated noninferior anti-ischaemic and antianginal efficacy to beta-blockers.

Methods: This systematic review and meta-analysis assessed the efficacy and safety of ivabradine in patients with stable angina pectoris who remained symptomatic despite receiving beta-blockers. Keyword searches of PubMed, The Cochrane Central Library Register, ClinicalTrials.gov, The World Health Organization International Clinical Trials Registry Platform (ICTRP) and Google Scholar identified studies comparing ivabradine plus beta-blockers with placebo or other first- or second-line antianginal agents in patients with stable angina pectoris. No date limits or language restrictions were applied. Outcomes were evaluated after 1 and 4 months of treatment, including changes in HR, angina attacks, use of short-acting nitrates, quality of life and safety. Risk of bias was evaluated on the basis of recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.

Results: Seven relevant studies were identified (N = 6821). Ivabradine plus a beta-blocker consistently reduced HR, anginal symptoms and short-acting nitrate consumption within 1 month of initiating therapy, with continued reductions for up to 4 months. Furthermore, ivabradine plus beta-blocker therapy was well tolerated, with bradycardia rarely reported (0.1% of patients overall). This study is limited by the inclusion of only two randomised studies, which may lead to result interpretation bias.

Conclusions: Ivabradine may be valuable for tailoring early antianginal treatment when used in combination with beta-blockers for chronic stable angina inadequately controlled by beta-blockers.

Citing Articles

A proposed tree-based explainable artificial intelligence approach for the prediction of angina pectoris.

Guldogan E, Yagin F, Pinar A, Colak C, Kadry S, Kim J Sci Rep. 2023; 13(1):22189.

PMID: 38092844 PMC: 10719282. DOI: 10.1038/s41598-023-49673-2.

References

Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif J . International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation. 2021; 144(7):512-523. PMC: 8360663. DOI: 10.1161/CIRCULATIONAHA.121.054567. View

Steg P, Greenlaw N, Tendera M, Tardif J, Ferrari R, Al-Zaibag M . Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014; 174(10):1651-9. DOI: 10.1001/jamainternmed.2014.3773. View

Perings S, Stockl G, Kelm M . Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice. Adv Ther. 2016; 33(9):1550-64. PMC: 5020130. DOI: 10.1007/s12325-016-0377-7. View

DiFrancesco D, Borer J . The funny current: cellular basis for the control of heart rate. Drugs. 2007; 67 Suppl 2:15-24. DOI: 10.2165/00003495-200767002-00003. View

Tendera M, Fox K, Ferrari R, Ford I, Greenlaw N, Abergel H . Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014; 176(1):119-24. DOI: 10.1016/j.ijcard.2014.06.052. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

Purpura C, Garry E, Honig N, Case A, Rassen J . The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Clin Pharmacol Ther. 2021; 111(1):135-144. PMC: 9299054. DOI: 10.1002/cpt.2474. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Andrews T, Fenton T, Toyosaki N, Glasser S, Young P, MacCallum G . Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation. 1993; 88(1):92-100. DOI: 10.1161/01.cir.88.1.92. View

10.

Werdan K, Perings S, Koster R, Kelm M, Meinertz T, Stockl G . Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies. Cardiology. 2016; 135(3):141-150. DOI: 10.1159/000447443. View

11.

Simon L, Ghaleh B, Puybasset L, Giudicelli J, Berdeaux A . Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995; 275(2):659-66. View

12.

Al-Lamee R, Thompson D, Dehbi H, Sen S, Tang K, Davies J . Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2017; 391(10115):31-40. DOI: 10.1016/S0140-6736(17)32714-9. View

13.

DiFrancesco D, Camm J . Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004; 64(16):1757-65. DOI: 10.2165/00003495-200464160-00003. View

14.

Manolis A, Ambrosio G, Collins P, Dechend R, Lopez-Sendon J, Pegoraro V . Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. Eur J Intern Med. 2019; 70:60-67. DOI: 10.1016/j.ejim.2019.09.013. View

15.

Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C . Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther. 2015; 32(8):757-67. PMC: 4569671. DOI: 10.1007/s12325-015-0237-x. View

16.

Ferrari R, Fox K . Heart rate reduction in coronary artery disease and heart failure. Nat Rev Cardiol. 2016; 13(8):493-501. DOI: 10.1038/nrcardio.2016.84. View

17.

Borer J, Le Heuzey J . Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008; 15(5):461-73. DOI: 10.1097/MJT.0b013e3181758855. View

18.

Glezer M, Vasyuk Y, Karpov Y . Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study). Adv Ther. 2018; 35(3):341-352. PMC: 5859687. DOI: 10.1007/s12325-018-0681-5. View

19.

Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J . A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015; 16:495. PMC: 4632358. DOI: 10.1186/s13063-015-1023-4. View

20.

Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T . Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol. 2010; 99(10):665-72. DOI: 10.1007/s00392-010-0172-4. View